foxo4-dri senolytic peptide human trial inhibitors targeting FOXO4-p53 interactions and inducing senescent cancer cell-specific apoptosis FOX04-DRI (10mg) – Nordsci
FOX04 DRI (10mg) Nordsci Buy FOXO4 DRI UK 98% Purity Next Day Dispatch FOXO4 DRI: Human Trial Status, Cancer Research & Senolytic Data The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications FOX04 DRI Apollo Peptide Sciences
Pay in 4 interest-free payments of $5.82 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10




